Inclusion Criteria:

• Aged ≥ 18 years;
• A history of chronic pseudo-obstruction for at least 3 months;
• Subjects with chronic idiopathic pseudo-obstruction or chronic pseudo-obstruction secondary to scleroderma or intestinal polyneuropathy;
• CIP had been diagnosed by a Barium-imaging study showing the presence of dilatation of any part of the small bowel (with or without the presence of large bowel dilatation);

Exclusion Criteria:

• Subjects with organic obstructing lesions causing intestinal obstruction;
• Current uncontrolled cardiovascular or lung disease, neurologic or psychiatric disorders (including substance abuse but with the exception of nicotin), alcoholism, cancer or AIDS and endocrine disorder;
• Impaired renal function
• A serum amylase, a serum glutamic-oxaloacetic transaminase (SGOT) or a serum glutamic-pyruvic transaminase (SGPT)concentration of > 2 times the normal limit;
• Laboratory values outside the reference range of the laboratory, unless explained by the disease or felt by the investigator to be clinically unimportant;
• Use of disallowed concomitant therapy;
• Female subjects who were pregnant or wished to become pregnant during the course of the trial or who were lactating;